Gregory H Pelton

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. pmc Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study
    Gregory H Pelton
    Late Life Depression Clinic, The Memory Disorders Center, and The Division of Geriatric Psychiatry, New York State Psychiatric Institute, NY, USA
    Int J Geriatr Psychiatry 23:670-6. 2008
  2. ncbi request reprint Usefulness of plasma haloperidol levels for monitoring clinical efficacy and side effects in Alzheimer patients with psychosis and behavioral dyscontrol
    Gregory H Pelton
    Department of Biological Psychiatry, New York State Psychiatric Institute, New York, NY 10032, USA
    Am J Geriatr Psychiatry 11:186-93. 2003
  3. ncbi request reprint PET network abnormalities and cognitive decline in patients with mild cognitive impairment
    Davangere P Devanand
    Department of Biological Psychiatry, College of Physicians and Surgeons, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    Neuropsychopharmacology 31:1327-34. 2006
  4. pmc Relapse risk after discontinuation of risperidone in Alzheimer's disease
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, New York 10032, USA
    N Engl J Med 367:1497-507. 2012
  5. ncbi request reprint Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment
    Matthias H Tabert
    Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, 1051 Riverside Dr, Unit 126, New York, NY 10032, USA
    Arch Gen Psychiatry 63:916-24. 2006
  6. pmc Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease
    Davangere P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Biol Psychiatry 64:871-9. 2008
  7. pmc Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls
    D P Devanand
    Division of Geriatric Psychiatry, Columbia University, New York, USA
    J Geriatr Psychiatry Neurol 23:185-98. 2010
  8. ncbi request reprint Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment
    D P Devanand
    Department of Biological Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Arch Neurol 62:975-80. 2005
  9. pmc (99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease
    D P Devanand
    NYSPI, Columbia University, New York, NY 10032, USA
    Am J Geriatr Psychiatry 18:959-72. 2010
  10. pmc Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon4 allele)
    Nikolaos Scarmeas
    Departments of Neurology, College of Physicians and Surgeons of Columbia University Medical Center 622 West 168th St, PH 19th floor New York, NY 10032, USA
    Am J Geriatr Psychiatry 12:596-605. 2004

Research Grants

Detail Information

Publications19

  1. pmc Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study
    Gregory H Pelton
    Late Life Depression Clinic, The Memory Disorders Center, and The Division of Geriatric Psychiatry, New York State Psychiatric Institute, NY, USA
    Int J Geriatr Psychiatry 23:670-6. 2008
    ..To assess combined antidepressant and cognitive enhancer treatment in elderly patients presenting with depression plus cognitive impairment...
  2. ncbi request reprint Usefulness of plasma haloperidol levels for monitoring clinical efficacy and side effects in Alzheimer patients with psychosis and behavioral dyscontrol
    Gregory H Pelton
    Department of Biological Psychiatry, New York State Psychiatric Institute, New York, NY 10032, USA
    Am J Geriatr Psychiatry 11:186-93. 2003
    ....
  3. ncbi request reprint PET network abnormalities and cognitive decline in patients with mild cognitive impairment
    Davangere P Devanand
    Department of Biological Psychiatry, College of Physicians and Surgeons, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    Neuropsychopharmacology 31:1327-34. 2006
    ..Independent replication in larger samples is needed before clinical application can be considered...
  4. pmc Relapse risk after discontinuation of risperidone in Alzheimer's disease
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, New York 10032, USA
    N Engl J Med 367:1497-507. 2012
    ..Among patients with Alzheimer's disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established...
  5. ncbi request reprint Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment
    Matthias H Tabert
    Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, 1051 Riverside Dr, Unit 126, New York, NY 10032, USA
    Arch Gen Psychiatry 63:916-24. 2006
    ..The likelihood of conversion to Alzheimer disease (AD) in mild cognitive impairment (MCI) and the "optimal" early markers of conversion need to be established...
  6. pmc Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease
    Davangere P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Biol Psychiatry 64:871-9. 2008
    ..The utility of combining early markers to predict conversion from mild cognitive impairment (MCI) to Alzheimer's Disease (AD) remains uncertain...
  7. pmc Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls
    D P Devanand
    Division of Geriatric Psychiatry, Columbia University, New York, USA
    J Geriatr Psychiatry Neurol 23:185-98. 2010
    ..These PET techniques provide complementary information in strongly distinguishing diagnostic groups in cross-sectional comparisons that need testing in longitudinal studies...
  8. ncbi request reprint Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment
    D P Devanand
    Department of Biological Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Arch Neurol 62:975-80. 2005
    ..In cognitively impaired patients without dementia, the utility of apolipoprotein E (APOE) genotyping is unclear...
  9. pmc (99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease
    D P Devanand
    NYSPI, Columbia University, New York, NY 10032, USA
    Am J Geriatr Psychiatry 18:959-72. 2010
    ..To examine the utility of single-photon emission computed tomography (SPECT) to predict conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD)...
  10. pmc Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon4 allele)
    Nikolaos Scarmeas
    Departments of Neurology, College of Physicians and Surgeons of Columbia University Medical Center 622 West 168th St, PH 19th floor New York, NY 10032, USA
    Am J Geriatr Psychiatry 12:596-605. 2004
    ..The authors investigated APOE-mediated differential brain activation in a group of healthy elderly subjects...
  11. ncbi request reprint Sertraline treatment of elderly patients with depression and cognitive impairment
    D P Devanand
    Late Life Depression Clinic, Memory Disorders Center, Department of Biological Psychiatry, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 26, New York, NY 10032, USA
    Int J Geriatr Psychiatry 18:123-30. 2003
    ....
  12. ncbi request reprint A 10-item smell identification scale related to risk for Alzheimer's disease
    Matthias H Tabert
    Department of Biological Psychiatry, New York State Psychiatric Institute, New York, NY, USA
    Ann Neurol 58:155-60. 2005
    ..Independent replication is needed to validate these findings...
  13. pmc A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, NY, USA
    Int J Geriatr Psychiatry 26:937-43. 2011
    ..In patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation...
  14. pmc The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, NY, USA
    Am J Geriatr Psychiatry 20:362-73. 2012
    ..Responders are randomized, double-blind, to one of three arms in Phase B: 1) continuation risperidone for the next 32 weeks, 2) risperidone for the next 16 weeks followed by placebo for 16 weeks, or 3) placebo for the next 32 weeks...
  15. ncbi request reprint Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder
    D P Devanand
    Late Life Depression Clinic, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 126, New York, NY 10032, USA
    Am J Geriatr Psychiatry 13:59-68. 2005
    ..The authors compared the efficacy and side effects of fluoxetine and placebo in elderly outpatients with dysthymic disorder...
  16. pmc Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance
    Nikolaos Scarmeas
    Cognitive Neuroscience Division of the Taub Institute for Research on Alzheimer s Disease and the Aging Brain, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA
    Neuroimage 23:35-45. 2004
    ..Expression of covariance patterns correlates with cognitive and functional performance measures, holding promise for meaningful associations with underlying biopathological processes...
  17. pmc Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): Clinical rationale and design
    Gregory H Pelton
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, NY, USA Department of Psychiatry, College of Physicians and Surgeons, Columbia University, NY, USA
    Contemp Clin Trials 37:200-8. 2014
    ..Apolipoprotein E ε4 status, odor identification deficits, and MRI entorhinal/hippocampal cortex atrophy at baseline are evaluated as neurobiological moderators of donepezil treatment effects. ..
  18. pmc A two-study comparison of clinical and MRI markers of transition from mild cognitive impairment to Alzheimer's disease
    D P Devanand
    Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, Unit 126, New York, NY 10032, USA
    Int J Alzheimers Dis 2012:483469. 2012
    ..The predictor models showed similar differences from each other in both studies, supporting independent validation. MRI hippocampal and entorhinal cortex volumes showed limited added predictive utility to memory and function measures...
  19. ncbi request reprint Vascular depression: overrepresented among African Americans?
    Michelle E Reinlieb
    The Graduate Center, City University of New York, New York, NY, USA UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA
    Int J Geriatr Psychiatry 29:470-7. 2014
    ..Secondary aims included characterizing the clinical and neuropsychological profile of vascular depression and comparing antidepressant response rates between patients with vascular and nonvascular depression...

Research Grants1

  1. Treating Mildly Cognitive- Impaired Depressed Elderly
    Gregory Pelton; Fiscal Year: 2005
    ....